CD34 and acute myeloid leukemia: CD34&CD38 most immature subpopulations may increase with poor-prognosis markers in both adults and the elderly.<h4>Conclusions</h4>Repositioning immunophenotypic analyses may offer a cost-effective alternative for refined prognostication, particularly in healthcare centers that already have flow cytometry-based AML diagnostics.